TITLE

AERAS/CRUCELL TO DEVELOP TB VACCINE

PUB. DATE
May 2004
SOURCE
Worldwide Biotech;May2004, Vol. 16 Issue 5, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the collaboration between Crucell NV and Aeras Global TB Vaccine Foundation of Bethesda, Maryland, on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Information on the Crucell-Aeras TB vaccine program; Details on Crucell's TV and malaria vaccine candidates.
ACCESSION #
13040767

 

Related Articles

  • CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL.  // Worldwide Biotech;Dec2006, Vol. 18 Issue 12, p3 

    The article reports on phase I clinical trial of the AdVac-based tuberculosis vaccine started by Crucell N.V. The vaccine is being developed in partnership with the AERAS Global TB Vaccine Foundation. The trial will test the vaccine in a dose-escalation trial involving healthy volunteers. AdVac...

  • Crucell receives $5 million for TB vaccine development.  // European Pharmaceutical Executive;May2007, p9 

    The article reports on the amount to be received by the Netherlands-based Crucell NV (CN) for developing a tuberculosis (TB) vaccine. CN will obtain up to $5 million from U.S.-based Aeras Global TB Vaccine Foundation to support the advanced development of the Advac-based TB vaccine. This...

  • Crucell and GlaxoSmithKline Biologicals partner to develop malaria vaccine.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p14 

    The article reports on the letter of agreement signed by Dutch biopharmaceutical company Crucell NV and GlaxoSmithKline (GSK) Biologicals SA to collaborate in developing a second generation malaria vaccine. It states that under the agreement, Crucell provides its malaria vaccine Ad35-CS based on...

  • News in brief.  // Nature Medicine;May2010, Vol. 16 Issue 5, p502 

    The article offers world news briefs related to medicine. It reports on the pledge of approximately 40 religious group representatives for stronger effort against HIV. It announces the combination of GlaxoSmithKline (GSK) and Crucell NV vaccine components to develop a malaria vaccine. It notes...

  • CLINIC ROUNDUP.  // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p2 

    This section offers news briefs related to the biotechnology industry. The first patient in the first phase of the clinical trial of CB3304 was enrolled by Cougar Biotechnology Inc. A Phase 1 BCG-Ad35 prime boost trial of a tuberculosis vaccine will be conducted by Crucell NV and Aeras Global TB...

  • A 2020 vision for vaccines against HIV, tuberculosis and malaria. Rappuoli, Rino; Aderem, Alan // Nature;5/26/2011, Vol. 473 Issue 7348, p463 

    Acquired immune deficiency syndrome (AIDS), malaria and tuberculosis collectively cause more than five million deaths per year, but have nonetheless eluded conventional vaccine development; for this reason they represent one of the major global public health challenges as we enter the second...

  • Vaccine Report.  // BioPharm International;Jun2010, Vol. 23 Issue 6, p12 

    The article offers news briefs related to vaccines including the announcement of Archivel Farma on the potential of its tuberculosis (TB) vaccine to cut treatment time from nine months to one month and the Crucell N.V.'s acquisition of 110 million U.S. dollars from UNICEF to supply its pediatric...

  • CLINIC ROUNDUP.  // BioWorld Today;4/29/2009, Vol. 20 Issue 81, p3 

    This section offers news briefs concerning the biotechnology industry. A Phase I trial of AERAS-402/Crucell Ad35 tuberculosis vaccine has been started by Crucell NV and the Aeras Global TB Vaccine Foundation. Inimex Pharmaceuticals Inc. has commenced its Phase I study of IMX942, an innate...

  • Mesenchymal stem cells as a novel vaccine platform. Tomchuck, Suzanne L.; Norton, Elizabeth B.; Garry, Robert F.; Bunnell, Bruce A.; Morris, Cindy A.; Freytag, Lucy C.; Clements, John D. // Frontiers in Cellular & Infection Microbiology;Oct2012, Vol. 2, p1 

    Vaccines are the most efficient and cost-effective means of preventing infectious disease. However, traditional vaccine approaches have thus far failed to provide protection against human immunodeficiency virus (HIV), tuberculosis, malaria and many other diseases. New approaches to vaccine...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics